

Stephan Menne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/896487/publications.pdf>

Version: 2024-02-01

62
papers

1,980
citations

230014

27
h-index

286692

43
g-index

62
all docs

62
docs citations

62
times ranked

1639
citing authors

#	ARTICLE	IF	CITATIONS
1	4-Oxo-octahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 58, 1285-18.	1.0	3
2	Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
3	Host cell-dependent late entry step as determinant of hepatitis B virus infection. <i>PLoS Pathogens</i> , 2022, 18, e1010633.	2.1	8
4	Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B. <i>Hepatology</i> , 2021, 73, 53-67.	3.6	56
5	Synthesis of 4-oxotetrahydropyrimidine-1(2H)-carboxamides derivatives as capsid assembly modulators of hepatitis B virus. <i>Medicinal Chemistry Research</i> , 2021, 30, 459-472.	1.1	6
6	Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B. <i>Viruses</i> , 2021, 13, 648.	1.5	8
7	Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 509-535.	0.8	11
8	Involvement of Innate Immune Receptors in the Resolution of Acute Hepatitis B in Woodchucks. <i>Frontiers in Immunology</i> , 2021, 12, 713420.	2.2	2
9	Characterization and Application of Precore/Core-Related Antigens in Animal Models of Hepatitis B Virus Infection. <i>Hepatology</i> , 2021, 74, 99-115.	3.6	19
10	Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks. <i>Cells</i> , 2021, 10, 2321.	1.8	6
11	Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects. <i>Frontiers in Immunology</i> , 2021, 12, 745802.	2.2	3
12	Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop. <i>Current HIV Research</i> , 2020, 18, 19-28.	0.2	9
13	Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon- α in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus. <i>Hepatology Communications</i> , 2020, 4, 916-931.	2.0	16
14	Suitability of the woodchuck HCC as a preclinical model for evaluation of intra-arterial therapies. <i>Animal Models and Experimental Medicine</i> , 2020, 3, 98-102.	1.3	7
15	Liver-Targeted Toll-Like Receptor 7 Agonist Combined With Entecavir Promotes a Functional Cure in the Woodchuck Model of Hepatitis B Virus. <i>Hepatology Communications</i> , 2019, 3, 1296-1310.	2.0	27
16	Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. <i>Cancers</i> , 2019, 11, 681.	1.7	33
17	Down-regulation of hepatitis delta virus super-infection in the woodchuck model. <i>Virology</i> , 2019, 531, 100-113.	1.1	3
18	The Genome Sequence of the Eastern Woodchuck (<i>Marmota monax</i>) – A Preclinical Animal Model for Chronic Hepatitis B. <i>G3: Genes, Genomes, Genetics</i> , 2019, 9, 3943-3952.	0.8	13

#	ARTICLE	IF	CITATIONS
19	Innate and adaptive immunity associated with resolution of acute woodchuck hepatitis virus infection in adult woodchucks. <i>PLoS Pathogens</i> , 2019, 15, e1008248.	2.1	17
20	Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. <i>Current Opinion in Virology</i> , 2018, 30, 9-17.	2.6	36
21	Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. <i>PLoS ONE</i> , 2018, 13, e0190058.	1.1	37
22	Prevention of liver tumor formation in woodchucks with established hepatocellular carcinoma by treatment with cationic liposome-DNA complexes. <i>BMC Cancer</i> , 2017, 17, 172.	1.1	13
23	Measurement of Antiviral Effect and Innate Immune Response During Treatment of Primary Woodchuck Hepatocytes. <i>Methods in Molecular Biology</i> , 2017, 1540, 277-294.	0.4	2
24	Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. <i>PLoS ONE</i> , 2017, 12, e0169631.	1.1	38
25	Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B. <i>PLoS ONE</i> , 2016, 11, e0161313.	1.1	56
26	Superinfection with Woodchuck Hepatitis Virus Strain WHVNY of Livers Chronically Infected with Strain WHV7. <i>Journal of Virology</i> , 2015, 89, 384-405.	1.5	13
27	Capacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks. <i>Virus Research</i> , 2015, 205, 12-21.	1.1	4
28	Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 62, 1237-1245.	1.8	191
29	Infection Patterns Induced in Naive Adult Woodchucks by Virions of Woodchuck Hepatitis Virus Collected during either the Acute or Chronic Phase of Infection. <i>Journal of Virology</i> , 2015, 89, 8749-8763.	1.5	7
30	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. <i>Journal of Hepatology</i> , 2015, 63, 329-336.	1.8	21
31	AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B. <i>PLoS ONE</i> , 2015, 10, e0144383.	1.1	18
32	Intrahepatic Transcriptional Signature Associated with Response to Interferon- α Treatment in the Woodchuck Model of Chronic Hepatitis B. <i>PLoS Pathogens</i> , 2015, 11, e1005103.	2.1	42
33	Envelope Proteins Derived from Naturally Integrated Hepatitis B Virus DNA Support Assembly and Release of Infectious Hepatitis Delta Virus Particles. <i>Journal of Virology</i> , 2014, 88, 5742-5754.	1.5	71
34	Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. <i>Hepatology</i> , 2013, 57, 13-22.	3.6	43
35	Expression of matrix metalloproteinases and their inhibitors in the woodchuck model of hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2013, 85, 1127-1138.	2.5	11
36	Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein. <i>Hepatology</i> , 2012, 56, 1240-1251.	3.6	42

#	ARTICLE	IF	CITATIONS
37	Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. <i>Hepatology</i> , 2012, 56, 76-85.	3.6	28
38	Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 474-483.	3.6	23
39	Transcriptomic analysis of the woodchuck model of chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 820-830.	3.6	88
40	Electroporation Enhances Immunogenicity of a DNA Vaccine Expressing Woodchuck Hepatitis Virus Surface Antigen in Woodchucks. <i>Journal of Virology</i> , 2011, 85, 4853-4862.	1.5	17
41	Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12. <i>Journal of Virology</i> , 2009, 83, 2663-2674.	1.5	34
42	Semliki Forest Virus Expressing Interleukin-12 Induces Antiviral and Antitumoral Responses in Woodchucks with Chronic Viral Hepatitis and Hepatocellular Carcinoma. <i>Journal of Virology</i> , 2009, 83, 12266-12278.	1.5	42
43	Correlation of Virus and Host Response Markers with Circulating Immune Complexes during Acute and Chronic Woodchuck Hepatitis Virus Infection. <i>Journal of Virology</i> , 2009, 83, 1579-1591.	1.5	13
44	Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant. <i>Journal of Medical Virology</i> , 2009, 81, 1760-1772.	2.5	11
45	Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3617-3632.	1.4	33
46	Antiviral Effect of Orally Administered (2R)-2-Aminopurine Dioxolane in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3177-3184.	1.4	9
47	Chemoimmunotherapy of Chronic Hepatitis B Virus Infection in the Woodchuck Model Overcomes Immunologic Tolerance and Restores T-Cell Responses to Pre-S and S Regions of the Viral Envelope Protein. <i>Journal of Virology</i> , 2007, 81, 10614-10624.	1.5	27
48	Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection. <i>Hepatology</i> , 2007, 45, 614-622.	3.6	24
49	The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2007, 13, 104.	1.4	150
50	Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2720-2728.	1.4	32
51	Measurement of Cell-Mediated Immune Response in Woodchucks. , 2004, 96, 27-36.		4
52	Kinetics of viremia and acute liver injury in relation to outcome of neonatal woodchuck hepatitis virus infection. <i>Journal of Medical Virology</i> , 2004, 72, 406-415.	2.5	17
53	Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. <i>Gastroenterology</i> , 2004, 127, S283-S293.	0.6	130
54	Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. <i>Antiviral Therapy</i> , 2004, 9, 937-52.	0.6	15

#	ARTICLE	IF	CITATIONS
55	Clevudine Therapy with Vaccine Inhibits Progression of Chronic Hepatitis and Delays Onset of Hepatocellular Carcinoma in Chronic Woodchuck Hepatitis Virus Infection. <i>Antiviral Therapy</i> , 2004, 9, 937-952.	0.6	44
56	Role of type 1 versus type 2 immune responses in liver during the onset of chronic woodchuck hepatitis virus infection. <i>Hepatology</i> , 2003, 37, 771-780.	3.6	34
57	Immunization with Surface Antigen Vaccine Alone and after Treatment with 1-(2-Fluoro-5-Methyl- β -D-Arabinofuranosyl)-Uracil (1-FMAU) Breaks Humoral and Cell-Mediated Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection. <i>Journal of Virology</i> , 2002, 76, 5305-5314.	1.5	81
58	Deficiencies in the Acute-Phase Cell-Mediated Immune Response to Viral Antigens Are Associated with Development of Chronic Woodchuck Hepatitis Virus Infection following Neonatal Inoculation. <i>Journal of Virology</i> , 2002, 76, 1769-1780.	1.5	82
59	Immunogenic Effects of Woodchuck Hepatitis Virus Surface Antigen Vaccine in Combination with Antiviral Therapy: Breaking of Humoral and Cellular Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection. <i>Intervirology</i> , 2002, 45, 237-250.	1.2	43
60	Real-time polymerase chain reaction assays for leukocyte CD and cytokine mRNAs of the Eastern woodchuck (<i>Marmota monax</i>). <i>Veterinary Immunology and Immunopathology</i> , 2002, 87, 97-105.	0.5	15
61	Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). <i>Nature Medicine</i> , 1999, 5, 1125-1126.	15.2	29
62	T-Cell Response to Woodchuck Hepatitis Virus (WHV) Antigens during Acute Self-Limited WHV Infection and Convalescence and after Viral Challenge. <i>Journal of Virology</i> , 1998, 72, 6083-6091.	1.5	61